High-throughput oncogene mutation profiling in human cancer

被引：0

作者：

Roman K Thomas

Alissa C Baker

Ralph M DeBiasi

Wendy Winckler

Thomas LaFramboise

William M Lin

Meng Wang

Whei Feng

Thomas Zander

Laura E MacConaill

Jeffrey C Lee

Rick Nicoletti

Charlie Hatton

Mary Goyette

Luc Girard

Kuntal Majmudar

Liuda Ziaugra

Kwok-Kin Wong

Stacey Gabriel

Rameen Beroukhim

Michael Peyton

Jordi Barretina

Amit Dutt

Caroline Emery

Heidi Greulich

Kinjal Shah

Hidefumi Sasaki

Adi Gazdar

John Minna

Scott A Armstrong

Ingo K Mellinghoff

F Stephen Hodi

Glenn Dranoff

Paul S Mischel

Tim F Cloughesy

Stan F Nelson

Linda M Liau

Kirsten Mertz

Mark A Rubin

Holger Moch

Massimo Loda

William Catalona

Jonathan Fletcher

Sabina Signoretti

Frederic Kaye

Kenneth C Anderson

George D Demetri

Reinhard Dummer

Stephan Wagner

Meenhard Herlyn

机构：

[1] Dana-Farber Cancer Institute,Department of Medical Oncology

[2] Harvard Medical School,Department of Surgery 2

[3] The Broad Institute of M.I.T. and Harvard,Department of Pathology

[4] 7 Cambridge Center,Departments of Internal Medicine and Pharmacology

[5] Hamon Center for Therapeutic Oncology Research,Department of Pediatric Oncology

[6] University of Texas Southwestern Medical Center at Dallas,Department of Molecular and Medical Pharmacology and Medicine

[7] 6000 Harry Hines Boulevard,Department of Pathology

[8] Nagoya City University Medical School,Department of Neurology

[9] University of Texas Southwestern Medical Center,Department of Human Genetics

[10] University of Texas Southwestern Medical Center,Department of Neurosurgery

[11] Dana-Farber Cancer Institute,Department of Pathology

[12] Harvard Medical School,Department of Urology

[13] David Geffen School of Medicine at the University of California,Department of Dermatology

[14] Los Angeles,Division of Immunology, Department of Dermatology

[15] David Geffen School of Medicine at the University of California,Department of Pathology

[16] Los Angeles,Center for Integrated Oncology and Department I for Internal Medicine

[17] David Geffen School of Medicine at the University of California,undefined

[18] Los Angeles,undefined

[19] David Geffen School of Medicine at the University of California,undefined

[20] Los Angeles,undefined

[21] David Geffen School of Medicine at the University of California,undefined

[22] Los Angeles,undefined

[23] Brigham and Women's Hospital,undefined

[24] Harvard Medical School,undefined

[25] Institute of Surgical Pathology,undefined

[26] University Hospital Zürich,undefined

[27] Northwestern University Feinberg School of Medicine,undefined

[28] Genetics Branch,undefined

[29] Center for Cancer Research,undefined

[30] National Cancer Institute and National Naval Medical Center,undefined

[31] Ludwig Center for Cancer Research at Dana-Farber Cancer Institute,undefined

[32] University Hospital Zürich,undefined

[33] Allergy and Infectious Diseases,undefined

[34] Medical University of Vienna,undefined

[35] and Center of Molecular Medicine,undefined

[36] Austrian Academy of Sciences,undefined

[37] Wahringer Gurtel 18-20,undefined

[38] The Wistar Institute,undefined

[39] Novartis Institutes for BioMedical Research,undefined

[40] Harvard Medical School,undefined

[41] Center for Cancer Genome Discovery,undefined

[42] Dana-Farber Cancer Institute,undefined

[43] Harvard Medical School,undefined

[44] Melanoma Program in Medical Oncology,undefined

[45] Dana-Farber Cancer Institute,undefined

[46] Harvard Medical School,undefined

[47] Max Planck Institute for Neurological Research with Klaus Joachim Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne,undefined

[48] University of Cologne,undefined

来源：

Nature Genetics | 2007年 / 39卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Systematic efforts are underway to decipher the genetic changes associated with tumor initiation and progression1,2. However, widespread clinical application of this information is hampered by an inability to identify critical genetic events across the spectrum of human tumors with adequate sensitivity and scalability. Here, we have adapted high-throughput genotyping to query 238 known oncogene mutations across 1,000 human tumor samples. This approach established robust mutation distributions spanning 17 cancer types. Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation. Moreover, we identified previously unrecognized oncogene mutations in several tumor types and observed an unexpectedly high number of co-occurring mutations. These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention.

引用

页码：347 / 351

页数：4

共 29 条

[1]

Sjoblom T(2006)The consensus coding sequences of human breast and colorectal cancers Science 314 268-274

[2]

Heinrich MC(2003)Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J. Clin. Oncol. 21 4342-4349

[3]

Thomas RK(2005)Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors Cold Spring Harb. Symp. Quant. Biol. 70 73-81

[4]

Paez JG(2004)EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-1500

[5]

Pao W(2004)EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. USA 101 13306-13311

[6]

Lynch TJ(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2129-2139

[7]

Solit DB(2006)BRAF mutation predicts sensitivity to MEK inhibition Nature 439 358-362

[8]

Thomas RK(2006)Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing Nat. Med. 12 852-855

[9]

Bansal A(2002)Association testing by DNA pooling: an effective initial screen Proc. Natl. Acad. Sci. USA 99 16871-16874

[10]

Werner M(2002)Large-scale determination of SNP allele frequencies in DNA pools using MALDI-TOF mass spectrometry Hum. Mutat. 20 57-64

← 1 2 3 →